Combination systemic therapies in psoriatic arthritis

References

• Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: A population-based study. J Rheumatol. 2009;36:361–367.
   PubMed Web of Science ®Google Scholar
• Gladman DD. Psoriatic arthritis. Dermatol Ther. 2009;22:40–55.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53:573.
   PubMed Web of Science ®Google Scholar
• Mease PJ. Psoriatic arthritis assessment and treatment update. Curr Opin Rheumatol. 2009;21:348–355.
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Gulfe A, Saxne T, Geborek P. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: Results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis. 2008;67:364–369.
   PubMed Web of Science ®Google Scholar
• Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–2673.
   PubMed Web of Science ®Google Scholar
• Fitzgerald O, Winchester R. Psoriatic arthritis: From pathogenesis to therapy. Arthritis Res Ther. 2009;11:214.
   PubMed Web of Science ®Google Scholar
• Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S, IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203:2577–2587.
   PubMed Web of Science ®Google Scholar
• Hong K, Chu A, Ludviksson BR, Berg EL, Ehrhardt RO. IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J Immunol. 1999;162:7480–7491.
   PubMed Web of Science ®Google Scholar
• McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: A 5-yr prospective study. Rheumatology (Oxford). 2003;42:778–783.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 1990;17:809–812.
   PubMed Web of Science ®Google Scholar
• Husted JA, Gladman DD, Farewell VT, Cook RJ. Health-related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis. Arthritis Rheum. 2001;45:151–158.
   PubMed Web of Science ®Google Scholar
• Kavanaugh AF, Ritchlin CT. Systematic review of treatments for psoriatic arthritis: An evidence based approach and basis for treatment guidelines. J Rheumatol. 2006;33:1417–1421.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264–2272.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Antoni CE, Gladman D, Wassenberg S, Zhou B, Beutler A, The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): Results of radiographic analyses after 1 year. Ann Rheum Dis. 2006;65:1038–1043.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279–3289.
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633–640.
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68:1387–1394.
   PubMed Web of Science ®Google Scholar
• Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): Cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci. 2008;11:81s–110s.
   PubMed Web of Science ®Google Scholar
• Braun J, Rau R. An update on methotrexate. Curr Opin Rheumatol. 2009;21:216–223.
   PubMed Web of Science ®Google Scholar
• Scarpa R, Peluso R, Atteno M, Manguso F, Spano A, Iervolino S, The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: Results of a pilot randomised 6-month trial with methotrexate. Clin Rheumatol. 2008;27:823–826.
   PubMed Web of Science ®Google Scholar
• Madan V, Griffiths CE. Systemic ciclosporin and tacrolimus in dermatology. Dermatol Ther. 2007;20:239–250.
   PubMed Web of Science ®Google Scholar
• Mazzanti G, Coloni L, De Sabbata G, Paladini G. Methotrexate and cyclosporin combined therapy in severe psoriatic arthritis. A pilot study. Acta Derm Venereol Suppl (Stockh). 1994;186:116–117.
   PubMed Web of Science ®Google Scholar
• Clark CM, Kirby B, Morris AD, Davison S, Zaki I, Emerson R, Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Dermatol. 1999;141:279–282.
   PubMed Web of Science ®Google Scholar
• Fraser AD, van Kuijk AW, Westhovens R, Karim Z, Wakefield R, Gerards AH, A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis. 2005;64:859–864.
   PubMed Web of Science ®Google Scholar
• Strober BE, Menon K. Alefacept for the treatment of psoriasis and other dermatologic diseases. Dermatol Ther. 2007;20:270–276.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Keystone EC. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: Results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2006;54:1638–1645.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Reich K. Alefacept with methotrexate for treatment of psoriatic arthritis: Open-label extension of a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2009;60:402–411.
   PubMed Web of Science ®Google Scholar
• Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007;47:383–496.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60:976–986.
   PubMed Web of Science ®Google Scholar
• Spadaro A, Ceccarelli F, Scrivo R, Valesini G. Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis. Ann Rheum Dis. 2008;67:1650–1651.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, Adalimumab for long-term treatment of psoriatic arthritis: Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 2007;56:476–488.
   PubMed Web of Science ®Google Scholar
• Antoni C, Dechant C, Hanns-Martin Lorenz PD, Wendler J, Ogilvie A, Lueftl M, Open-label study of infliximab treatment for psoriatic arthritis: Clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum. 2002;47:506–512.
   PubMed Web of Science ®Google Scholar
• Covelli M, Scioscia C, Iannone F, Lapadula G. Repeated infusions of low-dose infliximab plus methotrexate in psoriatic arthritis: Immediate benefits are not maintained after discontinuation of infliximab. Clin Exp Rheumatol. 2005;23:145–151.
   Google Scholar
• Goedkoop AY, Kraan MC, Picavet DI, de Rie MA, Teunissen MB, Bos JD, Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: A prospective single-centre study. Arthritis Res Ther. 2004;6:R326–R334.
   PubMed Web of Science ®Google Scholar
• Provenzano G, Termini A, Le Moli C, Rinaldi F. Efficacy of infliximab in psoriatic arthritis resistant to treatment with disease modifying antirheumatic drugs: An open pilot study. Ann Rheum Dis. 2003;62:680–681.
   PubMed Web of Science ®Google Scholar
• Rinaldi F, Provenzano G, Termini A, Spinello M, La Seta F. Long term infliximab treatment for severe psoriatic arthritis: Evidence of sustained clinical and radiographic response. Ann Rheum Dis. 2005;64:1375–1376.
   PubMed Web of Science ®Google Scholar
• Salvarani C, Cantini F, Olivieri I, Macchioni P, Padula A, Niccoli L, Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum. 2003;49:541–545.
   PubMed Web of Science ®Google Scholar
• Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52:1227–1236.
   PubMed Web of Science ®Google Scholar
• Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64:1150–1157.
   PubMed Web of Science ®Google Scholar
• Black RL, O'Brien WM, Vanscott EJ, Auerbach R, Eisen AZ, Bunim JJ. Methotrexate therapy in psoriatic arthritis; Double-blind study on 21 patients. JAMA. 1964;189:743–747.
   PubMed Web of Science ®Google Scholar
• Willkens RF, Williams HJ, Ward JR, Egger MJ, Reading JC, Clements PJ, Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. 1984;27:376–381.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet. 2000;356:385–390.
   PubMed Web of Science ®Google Scholar
• Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932–1939.
   PubMed Web of Science ®Google Scholar
• Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552–1563.
   PubMed Web of Science ®Google Scholar